Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with lenalidomide ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now ...